DiaMedica Therapeutics Inc. (DMAC)
The price, the headline numbers and the latest news, in one place.
DiaMedica Therapeutics Inc. (DMAC) Stock Price, Analysis & Data
| Bid | 4.68 |
| Market Cap | 349M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -37.5M |
| 0.97 | |
| -0.72 | |
| n/a | |
| -8.01 | |
| P/B (ttm) | 9.10 |
| P/S (ttm) | 0.00 |
| Earnings Date | Nov 11, 2026 |
| Ask | 8.6 |
| Volume | 123,612 |
| Avg. Volume (20D) | 190,429 |
| Open | 6.57 |
| Previous Close | 6.47 |
| Day's Range | 6.33 - 6.88 |
| 52-Week Range | 5.25 - 10.42 |
| Analyst | n/a |
| Price Target | 13 (100.93%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About DMAC
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company...
Financial Performance
In 2025, DiaMedica Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -32.77M, an increase of 34.05%.
Financial StatementsAnalyst Forecast
According to 4 analyst ratings, the average rating for DMAC stock is "null". The 12-month stock price forecast is 13, which is upside of 100.93% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.19 exceeds estimates by 0.01, with -5.56% YoY decline.
Analysts project revenue of ... Upgrade
